Skip to content

Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099568
Enrollment
Unknown
Registered
2025-03-25
Start date
2024-04-23
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Interventions

experimental group:Therapy of mesenchymal stem cell blood purification.

Sponsors

ZhuJiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age range from 18 to 65 years old; 2. Patients with acute liver failure in the early and intermediate stages caused by various reasons; 3. Total bilirubin (TBil) >= 171µmol/L or an increase of = 17.1µmol/L per day; 4. Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6); 5. No hepatic encephalopathy or encephalopathy below grade II (including grade II); 6. Elevated inflammatory markers (IL-6 / TNF-a / CRP, etc.); 7. The subjects are able to communicate well with the researchers and can complete the study in accordance with the study regulations; 8. The subjects must be informed of this study and voluntarily sign a written informed consent form before the experiment.

Exclusion criteria

Exclusion criteria: 1.Patients with severe active bleeding or diffuse intravascular coagulation; 2.Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine; 3.Patients with circulatory failure; 4.Patients with a MELD score > 30; 5.Patients with other severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes; 6.Subjects who may be unable to complete this study for other reasons or who the researchers believe should not be included.

Design outcomes

Primary

MeasureTime frame
Survival rate at 4 weeks after treatment;

Secondary

MeasureTime frame
conversion rate to liver transplantation;Liver disease score(MELD, MELD-Na, Child-Pugh, COSSH-ACLF ?s);Inflammatory(IL-6, TNF-a, CRP);Liver disease indicators(PTA, lactic aicd, blood ammonia, AFP, ferritin);Survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment;

Countries

China

Contacts

Public ContactKebo Zhong

ZhuJiang Hospital of Southern Medical University

zhongkb@smu.edu.cn+86 136 1146 7516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026